Amrapali Industries Limited

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, TATAELXSI.NS has a market cap of 267.7B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while TATAELXSI.NS trades at ₹4,321.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas TATAELXSI.NS's P/E ratio is 42.62. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to TATAELXSI.NS's ROE of +0.22%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TATAELXSI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TATAELXSI.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, TATAELXSI.BO has a market cap of 267.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while TATAELXSI.BO trades at ₹4,316.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas TATAELXSI.BO's P/E ratio is 46.05. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to TATAELXSI.BO's ROE of +0.22%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TATAELXSI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TATAELXSI.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, KFINTECH.NS has a market cap of 160B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while KFINTECH.NS trades at ₹918.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas KFINTECH.NS's P/E ratio is 46.28. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to KFINTECH.NS's ROE of +0.23%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KFINTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KFINTECH.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, KFINTECH.BO has a market cap of 159.9B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while KFINTECH.BO trades at ₹916.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas KFINTECH.BO's P/E ratio is 46.11. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to KFINTECH.BO's ROE of +0.23%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KFINTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KFINTECH.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, BBOX.NS has a market cap of 126.1B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while BBOX.NS trades at ₹749.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas BBOX.NS's P/E ratio is 59.07. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to BBOX.NS's ROE of +0.28%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to BBOX.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check BBOX.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, BBOX.BO has a market cap of 125.5B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while BBOX.BO trades at ₹748.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas BBOX.BO's P/E ratio is 58.70. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to BBOX.BO's ROE of +0.28%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to BBOX.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check BBOX.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, INTELLECT.NS has a market cap of 109.2B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while INTELLECT.NS trades at ₹804.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas INTELLECT.NS's P/E ratio is 30.59. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to INTELLECT.NS's ROE of +0.13%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to INTELLECT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check INTELLECT.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, INTELLECT.BO has a market cap of 109.1B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while INTELLECT.BO trades at ₹809.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas INTELLECT.BO's P/E ratio is 30.55. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to INTELLECT.BO's ROE of +0.13%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to INTELLECT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check INTELLECT.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, BLACKBUCK.NS has a market cap of 102B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while BLACKBUCK.NS trades at ₹577.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas BLACKBUCK.NS's P/E ratio is 26.75. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to BLACKBUCK.NS's ROE of +0.29%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to BLACKBUCK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check BLACKBUCK.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, TANLA.BO has a market cap of 76.1B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while TANLA.BO trades at ₹563.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas TANLA.BO's P/E ratio is 14.61. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to TANLA.BO's ROE of +0.22%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TANLA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TANLA.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, TANLA.NS has a market cap of 76.1B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while TANLA.NS trades at ₹561.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas TANLA.NS's P/E ratio is 15.01. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to TANLA.NS's ROE of +0.22%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TANLA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TANLA.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, RATEGAIN.NS has a market cap of 74.9B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while RATEGAIN.NS trades at ₹629.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas RATEGAIN.NS's P/E ratio is 41.75. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to RATEGAIN.NS's ROE of +0.10%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to RATEGAIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check RATEGAIN.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, RATEGAIN.BO has a market cap of 74.8B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while RATEGAIN.BO trades at ₹634.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas RATEGAIN.BO's P/E ratio is 41.75. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to RATEGAIN.BO's ROE of +0.10%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to RATEGAIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check RATEGAIN.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, NEWGEN.BO has a market cap of 70.8B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while NEWGEN.BO trades at ₹504.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas NEWGEN.BO's P/E ratio is 23.81. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to NEWGEN.BO's ROE of +0.19%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to NEWGEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check NEWGEN.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, NEWGEN.NS has a market cap of 70.7B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while NEWGEN.NS trades at ₹506.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas NEWGEN.NS's P/E ratio is 23.73. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to NEWGEN.NS's ROE of +0.19%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to NEWGEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check NEWGEN.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, MAPMYINDIA.NS has a market cap of 53B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while MAPMYINDIA.NS trades at ₹957.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas MAPMYINDIA.NS's P/E ratio is 40.34. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to MAPMYINDIA.NS's ROE of +0.17%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to MAPMYINDIA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check MAPMYINDIA.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, MAPMYINDIA.BO has a market cap of 52.9B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while MAPMYINDIA.BO trades at ₹955.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas MAPMYINDIA.BO's P/E ratio is 40.18. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to MAPMYINDIA.BO's ROE of +0.17%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to MAPMYINDIA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check MAPMYINDIA.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, EMUDHRA.NS has a market cap of 44B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while EMUDHRA.NS trades at ₹518.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas EMUDHRA.NS's P/E ratio is 43.20. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to EMUDHRA.NS's ROE of +0.14%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to EMUDHRA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check EMUDHRA.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, EMUDHRA.BO has a market cap of 44B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while EMUDHRA.BO trades at ₹519.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas EMUDHRA.BO's P/E ratio is 43.23. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to EMUDHRA.BO's ROE of +0.14%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to EMUDHRA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check EMUDHRA.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, NPST.NS has a market cap of 25.8B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while NPST.NS trades at ₹1,247.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas NPST.NS's P/E ratio is 69.06. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to NPST.NS's ROE of +0.19%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to NPST.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check NPST.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, KERNEX.NS has a market cap of 25.5B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while KERNEX.NS trades at ₹1,580.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas KERNEX.NS's P/E ratio is 48.38. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to KERNEX.NS's ROE of +0.35%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KERNEX.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KERNEX.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, KERNEX.BO has a market cap of 25.5B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while KERNEX.BO trades at ₹1,583.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas KERNEX.BO's P/E ratio is 47.28. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to KERNEX.BO's ROE of +0.35%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KERNEX.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KERNEX.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, NUCLEUS.BO has a market cap of 21.4B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while NUCLEUS.BO trades at ₹815.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas NUCLEUS.BO's P/E ratio is 14.71. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to NUCLEUS.BO's ROE of +0.18%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to NUCLEUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check NUCLEUS.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, NUCLEUS.NS has a market cap of 21.4B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while NUCLEUS.NS trades at ₹816.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas NUCLEUS.NS's P/E ratio is 14.57. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to NUCLEUS.NS's ROE of +0.18%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to NUCLEUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check NUCLEUS.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, RAMCOSYS.BO has a market cap of 15.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while RAMCOSYS.BO trades at ₹410.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas RAMCOSYS.BO's P/E ratio is 69.51. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to RAMCOSYS.BO's ROE of +0.07%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to RAMCOSYS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check RAMCOSYS.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, RAMCOSYS.NS has a market cap of 15.5B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while RAMCOSYS.NS trades at ₹414.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas RAMCOSYS.NS's P/E ratio is 69.46. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to RAMCOSYS.NS's ROE of +0.07%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to RAMCOSYS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check RAMCOSYS.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, MEGASOFT.NS has a market cap of 13.9B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while MEGASOFT.NS trades at ₹188.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas MEGASOFT.NS's P/E ratio is 7.91. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to MEGASOFT.NS's ROE of +0.77%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to MEGASOFT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check MEGASOFT.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, GENESYS.BO has a market cap of 11.4B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while GENESYS.BO trades at ₹263.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas GENESYS.BO's P/E ratio is 18.73. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to GENESYS.BO's ROE of +0.07%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to GENESYS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check GENESYS.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, GENESYS.NS has a market cap of 11.4B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while GENESYS.NS trades at ₹262.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas GENESYS.NS's P/E ratio is 28.28. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to GENESYS.NS's ROE of +0.07%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to GENESYS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check GENESYS.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, IZMO.BO has a market cap of 10.7B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while IZMO.BO trades at ₹708.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas IZMO.BO's P/E ratio is 28.83. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to IZMO.BO's ROE of +0.10%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to IZMO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check IZMO.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, IZMO.NS has a market cap of 10.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while IZMO.NS trades at ₹710.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas IZMO.NS's P/E ratio is 28.94. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to IZMO.NS's ROE of +0.10%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to IZMO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check IZMO.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, UNIECOM.NS has a market cap of 10.3B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while UNIECOM.NS trades at ₹95.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas UNIECOM.NS's P/E ratio is 51.62. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to UNIECOM.NS's ROE of +0.14%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to UNIECOM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check UNIECOM.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, TAC.NS has a market cap of 10.2B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while TAC.NS trades at ₹464.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas TAC.NS's P/E ratio is 71.28. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to TAC.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TAC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TAC.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, QUICKHEAL.NS has a market cap of 9.7B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while QUICKHEAL.NS trades at ₹215.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas QUICKHEAL.NS's P/E ratio is 177.60. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to QUICKHEAL.NS's ROE of +0.01%. Regarding short-term risk, AMRAPLIN.BO is less volatile compared to QUICKHEAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check QUICKHEAL.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, QUICKHEAL.BO has a market cap of 9.7B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while QUICKHEAL.BO trades at ₹215.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas QUICKHEAL.BO's P/E ratio is 175.83. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to QUICKHEAL.BO's ROE of +0.01%. Regarding short-term risk, AMRAPLIN.BO is less volatile compared to QUICKHEAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check QUICKHEAL.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, KODYTECH.NS has a market cap of 9.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while KODYTECH.NS trades at ₹771.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas KODYTECH.NS's P/E ratio is 60.92. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to KODYTECH.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KODYTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KODYTECH.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, KELLTONTEC.BO has a market cap of 8.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while KELLTONTEC.BO trades at ₹16.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas KELLTONTEC.BO's P/E ratio is 9.38. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to KELLTONTEC.BO's ROE of +0.16%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KELLTONTEC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KELLTONTEC.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, KELLTONTEC.NS has a market cap of 8.6B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while KELLTONTEC.NS trades at ₹16.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas KELLTONTEC.NS's P/E ratio is 9.36. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to KELLTONTEC.NS's ROE of +0.16%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KELLTONTEC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KELLTONTEC.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, INNOVANA.NS has a market cap of 8.2B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while INNOVANA.NS trades at ₹390.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas INNOVANA.NS's P/E ratio is 17.61. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to INNOVANA.NS's ROE of +0.20%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to INNOVANA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check INNOVANA.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, VEEFIN.BO has a market cap of 8B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while VEEFIN.BO trades at ₹311.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas VEEFIN.BO's P/E ratio is 45.83. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to VEEFIN.BO's ROE of +0.04%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to VEEFIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check VEEFIN.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, KSOLVES.BO has a market cap of 7B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while KSOLVES.BO trades at ₹292.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas KSOLVES.BO's P/E ratio is 22.90. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to KSOLVES.BO's ROE of +1.32%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KSOLVES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KSOLVES.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, KSOLVES.NS has a market cap of 7B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while KSOLVES.NS trades at ₹294.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas KSOLVES.NS's P/E ratio is 22.92. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to KSOLVES.NS's ROE of +1.32%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KSOLVES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KSOLVES.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, SUBEXLTD.NS has a market cap of 5.9B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while SUBEXLTD.NS trades at ₹11.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas SUBEXLTD.NS's P/E ratio is 528.00. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to SUBEXLTD.NS's ROE of +0.00%. Regarding short-term risk, AMRAPLIN.BO is less volatile compared to SUBEXLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SUBEXLTD.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, SOFTTECH.NS has a market cap of 5.7B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while SOFTTECH.NS trades at ₹427.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas SOFTTECH.NS's P/E ratio is 223.20. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to SOFTTECH.NS's ROE of +0.02%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SOFTTECH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SOFTTECH.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, SOFTTECH.BO has a market cap of 5.3B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while SOFTTECH.BO trades at ₹381.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas SOFTTECH.BO's P/E ratio is 205.24. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to SOFTTECH.BO's ROE of +0.02%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SOFTTECH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SOFTTECH.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, IRIS.NS has a market cap of 5.1B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while IRIS.NS trades at ₹246.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas IRIS.NS's P/E ratio is 50.32. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to IRIS.NS's ROE of +1.25%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to IRIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check IRIS.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, ABMKNO.BO has a market cap of 4.4B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while ABMKNO.BO trades at ₹229.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas ABMKNO.BO's P/E ratio is 38.95. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to ABMKNO.BO's ROE of +0.05%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to ABMKNO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check ABMKNO.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, XTGLOBAL.NS has a market cap of 4.4B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while XTGLOBAL.NS trades at ₹32.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas XTGLOBAL.NS's P/E ratio is 49.20. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to XTGLOBAL.NS's ROE of +0.06%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to XTGLOBAL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check XTGLOBAL.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, INFOBEAN.BO has a market cap of 4.2B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while INFOBEAN.BO trades at ₹172.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas INFOBEAN.BO's P/E ratio is 19.57. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to INFOBEAN.BO's ROE of +0.24%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to INFOBEAN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check INFOBEAN.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, INFOBEAN.NS has a market cap of 4.2B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while INFOBEAN.NS trades at ₹171.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas INFOBEAN.NS's P/E ratio is 19.52. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to INFOBEAN.NS's ROE of +0.24%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to INFOBEAN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check INFOBEAN.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, SYSTANGO.NS has a market cap of 4.1B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while SYSTANGO.NS trades at ₹276.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas SYSTANGO.NS's P/E ratio is 12.71. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to SYSTANGO.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SYSTANGO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SYSTANGO.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, TRACXN.BO has a market cap of 3.9B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while TRACXN.BO trades at ₹35.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas TRACXN.BO's P/E ratio is -30.27. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to TRACXN.BO's ROE of -0.20%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TRACXN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TRACXN.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, TRACXN.NS has a market cap of 3.9B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while TRACXN.NS trades at ₹35.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas TRACXN.NS's P/E ratio is -30.17. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to TRACXN.NS's ROE of -0.20%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TRACXN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TRACXN.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, DANLAW.BO has a market cap of 3.8B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while DANLAW.BO trades at ₹814.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas DANLAW.BO's P/E ratio is 19.44. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to DANLAW.BO's ROE of +0.26%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to DANLAW.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check DANLAW.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, MOS.NS has a market cap of 3.2B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while MOS.NS trades at ₹13.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas MOS.NS's P/E ratio is 22.64. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to MOS.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to MOS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check MOS.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, TREJHARA.NS has a market cap of 2.5B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while TREJHARA.NS trades at ₹174.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas TREJHARA.NS's P/E ratio is 64.50. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to TREJHARA.NS's ROE of +0.03%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TREJHARA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TREJHARA.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, TREJHARA.BO has a market cap of 2.5B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while TREJHARA.BO trades at ₹174.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas TREJHARA.BO's P/E ratio is 64.61. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to TREJHARA.BO's ROE of +0.03%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TREJHARA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TREJHARA.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, PROPEQUITY.NS has a market cap of 2.3B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while PROPEQUITY.NS trades at ₹215.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas PROPEQUITY.NS's P/E ratio is 17.31. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to PROPEQUITY.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to PROPEQUITY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check PROPEQUITY.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, VIAANINDUS.BO has a market cap of 2.1B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while VIAANINDUS.BO trades at ₹1,940.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas VIAANINDUS.BO's P/E ratio is -250.65. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to VIAANINDUS.BO's ROE of +1.43%. Regarding short-term risk, AMRAPLIN.BO is less volatile compared to VIAANINDUS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check VIAANINDUS.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, AVANCE.BO has a market cap of 2B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while AVANCE.BO trades at ₹1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas AVANCE.BO's P/E ratio is 100.00. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to AVANCE.BO's ROE of +0.00%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to AVANCE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check AVANCE.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, VIRINCHI.NS has a market cap of 1.9B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while VIRINCHI.NS trades at ₹17.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas VIRINCHI.NS's P/E ratio is -11.06. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to VIRINCHI.NS's ROE of -0.03%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to VIRINCHI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check VIRINCHI.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, VIRINCHI.BO has a market cap of 1.9B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while VIRINCHI.BO trades at ₹17.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas VIRINCHI.BO's P/E ratio is -10.97. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to VIRINCHI.BO's ROE of -0.03%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to VIRINCHI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check VIRINCHI.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, 7SEASL.BO has a market cap of 1.8B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while 7SEASL.BO trades at ₹81.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas 7SEASL.BO's P/E ratio is 84.75. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to 7SEASL.BO's ROE of +0.10%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to 7SEASL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check 7SEASL.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, CALSOFT.NS has a market cap of 1.4B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while CALSOFT.NS trades at ₹24.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas CALSOFT.NS's P/E ratio is 127.28. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to CALSOFT.NS's ROE of +0.37%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to CALSOFT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check CALSOFT.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, CALSOFT.BO has a market cap of 1.4B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while CALSOFT.BO trades at ₹23.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas CALSOFT.BO's P/E ratio is 125.94. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to CALSOFT.BO's ROE of +0.37%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to CALSOFT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check CALSOFT.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, CNIRESLTD.BO has a market cap of 1.2B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while CNIRESLTD.BO trades at ₹10.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas CNIRESLTD.BO's P/E ratio is -23.89. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to CNIRESLTD.BO's ROE of -0.12%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to CNIRESLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check CNIRESLTD.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, CURAA.NS has a market cap of 1.1B. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while CURAA.NS trades at ₹92.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas CURAA.NS's P/E ratio is -383.35. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to CURAA.NS's ROE of -0.03%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to CURAA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check CURAA.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, SGLRES.BO has a market cap of 869.2M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while SGLRES.BO trades at ₹3.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas SGLRES.BO's P/E ratio is 173.50. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to SGLRES.BO's ROE of -0.00%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SGLRES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SGLRES.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, ODYSSEY.BO has a market cap of 864.6M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while ODYSSEY.BO trades at ₹51.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas ODYSSEY.BO's P/E ratio is 21.57. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to ODYSSEY.BO's ROE of +0.07%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to ODYSSEY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check ODYSSEY.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, SECURKLOUD.BO has a market cap of 773.1M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while SECURKLOUD.BO trades at ₹23.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas SECURKLOUD.BO's P/E ratio is -4.15. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to SECURKLOUD.BO's ROE of -8.74%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SECURKLOUD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SECURKLOUD.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, SECURKLOUD.NS has a market cap of 767.8M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while SECURKLOUD.NS trades at ₹22.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas SECURKLOUD.NS's P/E ratio is -4.01. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to SECURKLOUD.NS's ROE of -8.74%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SECURKLOUD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SECURKLOUD.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, ORCHASP.NS has a market cap of 727.5M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while ORCHASP.NS trades at ₹1.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas ORCHASP.NS's P/E ratio is -52.50. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to ORCHASP.NS's ROE of +0.04%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to ORCHASP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check ORCHASP.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, VIRTUALS.BO has a market cap of 691.6M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while VIRTUALS.BO trades at ₹20.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas VIRTUALS.BO's P/E ratio is -14.77. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to VIRTUALS.BO's ROE of +0.08%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to VIRTUALS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check VIRTUALS.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, AEONXDIGI.BO has a market cap of 689.1M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while AEONXDIGI.BO trades at ₹148.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas AEONXDIGI.BO's P/E ratio is 46.38. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to AEONXDIGI.BO's ROE of +0.05%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to AEONXDIGI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check AEONXDIGI.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, JUPITERIN.BO has a market cap of 641.2M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while JUPITERIN.BO trades at ₹65.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas JUPITERIN.BO's P/E ratio is -35.95. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to JUPITERIN.BO's ROE of -0.04%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to JUPITERIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check JUPITERIN.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, SOFCOM.BO has a market cap of 605.1M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while SOFCOM.BO trades at ₹25.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas SOFCOM.BO's P/E ratio is 27.47. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to SOFCOM.BO's ROE of +0.01%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SOFCOM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SOFCOM.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, CRANESSOFT.BO has a market cap of 537.9M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while CRANESSOFT.BO trades at ₹3.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas CRANESSOFT.BO's P/E ratio is -2.02. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to CRANESSOFT.BO's ROE of +0.03%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to CRANESSOFT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check CRANESSOFT.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, NETLINK.BO has a market cap of 521.1M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while NETLINK.BO trades at ₹199.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas NETLINK.BO's P/E ratio is 515.13. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to NETLINK.BO's ROE of +0.00%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to NETLINK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check NETLINK.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, SAGARSOFT.BO has a market cap of 466.7M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while SAGARSOFT.BO trades at ₹74.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas SAGARSOFT.BO's P/E ratio is -214.74. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to SAGARSOFT.BO's ROE of -0.00%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SAGARSOFT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SAGARSOFT.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, RAMINFO.BO has a market cap of 423.9M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while RAMINFO.BO trades at ₹51.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas RAMINFO.BO's P/E ratio is 17.97. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to RAMINFO.BO's ROE of +0.05%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to RAMINFO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check RAMINFO.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, SAWABUSI.BO has a market cap of 377.6M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while SAWABUSI.BO trades at ₹0.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas SAWABUSI.BO's P/E ratio is 8.25. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to SAWABUSI.BO's ROE of -0.02%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to SAWABUSI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check SAWABUSI.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, TELECANOR.BO has a market cap of 359.6M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while TELECANOR.BO trades at ₹30.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas TELECANOR.BO's P/E ratio is -92.58. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to TELECANOR.BO's ROE of -1.77%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TELECANOR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TELECANOR.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, HOMESFY.NS has a market cap of 349.4M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while HOMESFY.NS trades at ₹120.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas HOMESFY.NS's P/E ratio is 25.70. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to HOMESFY.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to HOMESFY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check HOMESFY.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, MICROPRO.NS has a market cap of 287.4M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while MICROPRO.NS trades at ₹20.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas MICROPRO.NS's P/E ratio is -12.04. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to MICROPRO.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to MICROPRO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check MICROPRO.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, AHASOLAR.BO has a market cap of 283.6M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while AHASOLAR.BO trades at ₹92.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas AHASOLAR.BO's P/E ratio is 14.44. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to AHASOLAR.BO's ROE of +0.12%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to AHASOLAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check AHASOLAR.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, TELESYS.BO has a market cap of 282.5M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while TELESYS.BO trades at ₹13.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas TELESYS.BO's P/E ratio is N/A. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to TELESYS.BO's ROE of +0.01%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TELESYS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TELESYS.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, YUDIZ.NS has a market cap of 282.2M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while YUDIZ.NS trades at ₹28.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas YUDIZ.NS's P/E ratio is -24.42. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to YUDIZ.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to YUDIZ.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check YUDIZ.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, WESTLEIRES.BO has a market cap of 274.2M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while WESTLEIRES.BO trades at ₹94.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas WESTLEIRES.BO's P/E ratio is -264.12. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to WESTLEIRES.BO's ROE of -0.01%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to WESTLEIRES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check WESTLEIRES.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, RADIOWALLA.NS has a market cap of 270.3M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while RADIOWALLA.NS trades at ₹36.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas RADIOWALLA.NS's P/E ratio is 39.95. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to RADIOWALLA.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to RADIOWALLA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check RADIOWALLA.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, ERPSOFT.BO has a market cap of 243.5M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while ERPSOFT.BO trades at ₹61.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas ERPSOFT.BO's P/E ratio is 68.33. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to ERPSOFT.BO's ROE of +0.01%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to ERPSOFT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check ERPSOFT.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, KASHYAP.BO has a market cap of 240.5M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while KASHYAP.BO trades at ₹5.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas KASHYAP.BO's P/E ratio is -126.00. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to KASHYAP.BO's ROE of -0.30%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to KASHYAP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check KASHYAP.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, TRIDHYA.NS has a market cap of 218.9M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while TRIDHYA.NS trades at ₹9.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas TRIDHYA.NS's P/E ratio is -6.14. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to TRIDHYA.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to TRIDHYA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check TRIDHYA.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, COSYN.BO has a market cap of 166.3M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while COSYN.BO trades at ₹22.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas COSYN.BO's P/E ratio is 110.85. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to COSYN.BO's ROE of +0.01%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to COSYN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check COSYN.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, CONTCHM.BO has a market cap of 139.2M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while CONTCHM.BO trades at ₹64.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas CONTCHM.BO's P/E ratio is 22.26. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to CONTCHM.BO's ROE of +0.09%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to CONTCHM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check CONTCHM.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, OTCO.BO has a market cap of 139.1M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while OTCO.BO trades at ₹10.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas OTCO.BO's P/E ratio is -39.74. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to OTCO.BO's ROE of -0.13%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to OTCO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check OTCO.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, DHTL.NS has a market cap of 138.6M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while DHTL.NS trades at ₹44.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas DHTL.NS's P/E ratio is -6.84. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to DHTL.NS's ROE of N/A. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to DHTL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check DHTL.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, IFINSER.BO has a market cap of 102.7M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while IFINSER.BO trades at ₹14.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas IFINSER.BO's P/E ratio is 6.74. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to IFINSER.BO's ROE of +0.06%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to IFINSER.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check IFINSER.BO's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, MELSTAR.NS has a market cap of 71.9M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while MELSTAR.NS trades at ₹4.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas MELSTAR.NS's P/E ratio is 0.01. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to MELSTAR.NS's ROE of -0.39%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to MELSTAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check MELSTAR.NS's competition here

AMRAPLIN.BO plays a significant role within the Technology sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, AMRAPLIN.BO stands at 933.1M. In comparison, VIRGOGLOB.BO has a market cap of 68.6M. Regarding current trading prices, AMRAPLIN.BO is priced at ₹18.20, while VIRGOGLOB.BO trades at ₹6.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

AMRAPLIN.BO currently has a P/E ratio of 19.52, whereas VIRGOGLOB.BO's P/E ratio is -29.68. In terms of profitability, AMRAPLIN.BO's ROE is +0.15%, compared to VIRGOGLOB.BO's ROE of -0.95%. Regarding short-term risk, AMRAPLIN.BO is more volatile compared to VIRGOGLOB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for AMRAPLIN.BO.Check VIRGOGLOB.BO's competition here